Incyte Points To Niktimvo, Three Near-Term Approvals For Growth

10 Feb 2025

With Jakafi slated to lose US patent protection in 2028, Incyte is looking to GVHD launch product Niktimvo and label expansions for Opzelura, Monjuvi and Zynyz to drive late-decade growth.

Incyte points to pending approvals, Phase III readouts and initiations as potential growth drivers (Shutterstock)

As the loss of exclusivity for Incyte’s top-seller Jakafi (ruxolitinib) looms in 2028, the firm is making the case that other opportunities will deliver growth for the rest of the decade. Recently launched Niktimvo (axatilimab) and label expansions for Opzelura (ruxolitinib cream), Monjuvi (tafasitinib) and Zynyz (retifanlimab) will collectively generate an additional $1bn in revenue for the company by 2029, CEO Herve Hoppenot predicted during the firm’s fourth-quarter and full-year 2024 earnings call on 10 February, and there are more opportunities advancing through the pipeline.

Key Takeaways

Incyte reported Q4 and full-year sales growth led by Jakafi and Opzelura, but put emphasis on a recent launch and expected approvals and pivotal readouts.

Each of those products or new indications should reach the market before the end of 2025, the exec added, with Incyte planning to leverage its commercial infrastructure for Jakafi, Opzelura,...

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

23 May 2025

• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

21 May 2025

• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

20 May 2025

• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

20 May 2025

• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

15 May 2025

• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.